NCT03785366已完成3 期
A Randomized, Single-Blind, Comparative Bioavailability Study to Assess the Pharmacokinetic Properties of VeraCept® Intrauterine Contraceptive vs ParaGard® in Healthy, Post-Menarcheal Women
Sebela Women's Health Inc.2 个研究点 分布在 1 个国家目标入组 41 人开始时间: 2018年12月17日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 41
- 试验地点
- 2
- 主要终点
- Relative Maximum Observed Total Serum Copper Concentration of VeraCept vs ParaGard (Cmax)
研究概览
简要总结
to Assess the Pharmacokinetic Properties of VeraCept® Intrauterine Contraceptive vs ParaGard® in Healthy, Post- Menarcheal Women
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Single (Participant)
盲法说明
Subjects are blinded until the Day 57 Visit
入排标准
- 年龄范围
- — 至 45 Years（Child, Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Post-menarcheal, pre-menopausal females up to 45 years of age at the time of informed consent/assent and in good general health;
- •History of regular menstrual cycles defined as occurring every 21-35 days when not using hormones or prior to recent pregnancy or spontaneous or induced abortion;
- •Sexually active with a male partner who has not had a vasectomy;
- •Reasonably expect to have coitus at least once monthly during the study period;
- •In a mutually monogamous relationship of at least 3 months duration;
- •Seeking to avoid pregnancy for the duration of the study;
- •Willing to use the study drug as the sole form of contraception;
- •Willing to accept a risk of pregnancy;
- •Subjects who are age 21 or older, at time of informed consent, must have a normal papanicolaou test (Pap) or atypical squamous cells of undetermined significance (ASC-US) with negative high risk human papilloma virus (HPV) test result within the appropriate screen timeframe per American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines, and prior to the study IUD insertion. Alternatively, the subject must have had a colposcopy performed within the appropriate screen timeframe, and prior to the study IUD insertion that showed no evidence of dysplasia requiring treatment per ASCCP guidelines, or treatment was performed and follow-up at least 6 months after the treatment showed no evidence of disease by clinical evaluation;
- •Able and willing to comply with all study tests, procedures, assessment tools and follow-up;
- •Able and willing to provide and document informed consent and Authorization for Release of Protected Health Information (PHI). Unemancipated subjects under 18 years old must provide assent and have written parental consent documented on the consent form consistent with local legal requirements;
- •Plan to reside within a reasonable driving distance of a research site for the duration of the study.
- •Subject agrees not to self-remove VeraCept
排除标准
- •Known or suspected pregnancy; or at risk for pregnancy from unprotected intercourse earlier in current cycle;
- •A previously inserted intrauterine device (IUD) that has not been removed by the time the study IUD is placed;
- •History of previous IUD complications, such as perforation, expulsion, or pregnancy with IUD in place;
- •Pain with current IUD;
- •Use of ParaGard IUD within the past 3 months
- •Planned use of any non-contraceptive estrogen, progesterone or testosterone any time during the 60 months of study participation;
- •Exclusively breastfeeding before return of menses; lactating women will be excluded unless they have had 2 normal menstrual periods prior to enrollment;
- •Unexplained abnormal uterine bleeding (suspicious for a serious condition), including bleeding 4 weeks post-septic abortion or puerperal sepsis;
- •Severely heavy or painful menstrual bleeding;
- •Suspected or known cervical, uterine or ovarian cancer, or unresolved clinically significant abnormal Pap smear requiring evaluation or treatment;
- •Any history of gestational trophoblastic disease with or without detectable elevated ß-human chorionic gonadotropin (ß-hCG) levels, or related malignant disease;
- •Any congenital or acquired uterine anomaly that may complicate study drug placement, such as:
- •Submucosal uterine leiomyoma
- •Asherman's syndromes
- •Pedunculated polyps
- •Bicornuate uterus
- •Didelphus or uterine septa
- •Any distortions of the uterine cavity (e.g. fibroids), that, in the opinion of the investigator, are likely to cause issues during insertion, retention or removal of the IUD;
- •Untreated acute cervicitis or vaginitis within the past 3 months;
- •Known or suspected human immunodeficiency virus (HIV) infection or clinical AIDS;
- •Subjects who have an established immunodeficiency;
- •Known intolerance or allergy to any components of VeraCept or ParaGard including intolerance or allergy to nickel, titanium, or copper, and including Wilson's Disease;
- •Currently participating or planning future participation in a research study of an investigational drug or device during the course of this investigational study. Subject must have waited at least 30 days from exiting their last study prior to informed consent in this study;
- •Subject has been enrolled in a previous VeraCept study;
- •Known or suspected alcohol or drug abuse within 12 months prior to the screening visit;
- •Any general health, mental health or behavioral condition that, in the opinion of the investigator, could represent an increased risk for the subject or would render the subject less likely to provide the needed study information;
- •Study staff or a member of the immediate family of study staff.
- •Concurrent use of corticosteroids
研究组 & 干预措施
VeraCept
Experimental
VeraCept subjects will be inserted with VeraCept on Day 1. At Day 57 subjects will be informed that they received VeraCept and may continue in the study for up to 5 years
干预措施: VeraCept (Drug)
ParaGard
Active Comparator
ParaGard subjects will be inserted with ParaGard on Day 1. At Day 57 subjects will be informed that they received ParaGard and may choose to have the ParaGard removed or continue use per standard of clinical care.
干预措施: ParaGard (Drug)
结局指标
主要结局
Relative Maximum Observed Total Serum Copper Concentration of VeraCept vs ParaGard (Cmax)
时间窗: Study Days Baseline (pre-insertion), 3, 8, 15, 22, 29, 57
Assess the relative bioavailability of observed systemic copper from VeraCept versus ParaGard based on Cmax
Maximum Serum Concentration of Copper for VeraCept vs. ParaGard (AUC0-56)
时间窗: From Baseline (pre-insertion) through the last measurable non-zero concentration, up to Day 57 (56 days post-insertion), with a minimum of 50 days post-insertion required for inclusion.
Assess the maximum relative bioavailability of observed systemic serum levels of copper from VeraCept versus ParaGard based on AUC0-56
Mean Serum Concentration of Copper for VeraCept vs. ParaGard (Cmean)
时间窗: Study Days Baseline (pre-insertion), 3, 8, 15, 22, 29, 57
Assess the relative bioavailability of observed systemic copper from VeraCept versus ParaGard based on Cmean
次要结局
- Baseline-corrected Maximum Total Serum Copper Concentration of VeraCept vs. ParaGard (Cmax)(Study Days Baseline (pre-insertion), 3, 8, 15, 22, 29, 57)
- Baseline-Corrected Maximum Serum Concentration of Copper for VeraCept vs. ParaGard (AUC0-56)(Study Days Baseline (pre-insertion), 3, 8, 15, 22, 29, 57)
- Total Serum Copper Levels of VeraCept vs. ParaGard Compared to Normal Copper Levels(Study Days Baseline (pre-insertion), 3, 8, 15, 22, 29, 57 (VeraCept and ParaGard), Months 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 (VeraCept only))
- Long-term Stability of Copper Levels as Determined by Cmax - VeraCept Only(Study Days Baseline (pre-insertion), 3, 8, 15, 22, 29, 57, Months 6, 12, 18, 24, 30, 36, 42, 48, 54, 60)
- Long-term Stability of Copper Levels as Determined by Cmean - VeraCept Only(Study Days Baseline (pre-insertion), 3, 8, 15, 22, 29, 57, Months 6, 12, 18, 24, 30, 36, 48, 60)
- Baseline-corrected Mean Total Serum Copper Concentration of VeraCept vs. ParaGard (Cmean)(Study Days Baseline (pre-insertion), 3, 8, 15, 22, 29, 57)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
3 期
Evaluation of Efficacy, Safety and Tolerability of VeraCept IUSWomen at Risk for PregnancyNCT03633799Sebela Women's Health Inc.1,620
已完成
1 期
Comparative Study of the VeraCept Low-Dose Intrauterine Copper Contraceptive vs. the TCu380 Copper IUDPrevention of PregnancyNCT02167763Sebela Women's Health Inc.300
终止
2 期
To Investigate the Pharmacological Effects, Drug Blood Levels and Safety of an Intrauterine System Releasing the Study Drug BAY1007626 in Comparison to Mirena and Jaydess in Healthy Young Women Treated for 90 Days to Determine the Drug Dose for Further DevelopmentContraceptionNCT02490774Bayer174
已完成
3 期
E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia StudyContraceptionNCT02817828Estetra1,577
已完成
3 期
E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada StudyContraceptionNCT02817841Estetra2,148